For previously treated myelofibrosis, the novel JAK inhibitor momelotinib (GlaxoSmithKline) appears to offer a broader range of symptom control than the currently approved JAK inhibitors for the disease, ruxolitinib (Opzelura, Incyte) and fedratinib (Inrebic, Bristol Myers Squibb), according to results of a phase 3 trial called MOMENTUM.
“With currently approved therapies not having a significant ability to reduce transfusion dependence, momelotinib can be considered a major